Navigation Links
Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents

stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit www.OrbusNeich.com.

    Global Media Contacts:


    David Schull

    Russo Partners LLC

    +1 212-845-4271 (office)

    +1 858-717-2310 (mobile)

    


    Benjamin Carmichael

    +1 212-845-4242
david.schull@russopartnersllc.com benjamin.carmichael@russopartnersllc.com

CONTACT: David Schull, +1-212-845-4271 office, +1-858-717-2310 mobile,, or Benjamin Carmichael, +1-212-845-4242,, both of Russo Partners LLC forOrbusNeich david.schull@russopartnersllc.com benjamin.carmichael@russopartnersllc.com

Web site: http://www.OrbusNeich.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
9. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
10. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
11. Studies Show Efficacy and Safety of Alexions Soliris in Broad Population of PNH Patients
Post Your Comments:
(Date:8/27/2008)...l, expected by mid-2009 - - Data from second Phas...KVILLE, Md., Aug. 27 /- Hum...nounced it has completed enrollment,and initial do...3,randomized clinical trials of LymphoStat-B(R) (b...rythematosus (SLE). Belimumab is being developed b...
(Date:8/26/2008)... SYNTAX clinical trial, NATICK, Mass., Aug. 26 /P...ion (NYSE: BSX ) today announced the schedule of ... at the European Society of Cardiology,Congress 20...nich, Germany., The Company plans to announce 12-...ercutaneous coronary intervention (PCI) using the ...
(Date:8/26/2008)...afore Pharmaceuticals Inc.,presented data at the S...s,in Cancer in Washington, D.C., announcing the di...that demonstrate significant anticancer,activity i...olecular scaffold has been developed using,computa... kinase inhibitors,as well as isoform-selective sm...
(Date:8/26/2008)...- Healthpoint today announced,that it has initiate...f a,widely prescribed enzymatic debriding agent on... pilot study was prompted, in part, by clinical re...rs and beneficial healing,properties associated wi...he findings from the peer-reviewed literature, as ...
Breaking Medicine Technology:Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 1Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 18915 2Roches Vidal Honored as 2008 HBA Rising Star 18911 1Roches Vidal Honored as 2008 HBA Rising Star 18911 2American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 1American Red Cross of Southeastern Michigan Celebrates Outstanding Volunteers for Years of Service 18906 2International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 1International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 5268 2
...-Apr 16, 2007 - Amgen,(Nasdaq:AMGN) today presente...cebo-controlled Phase 3 study evaluating the,effic...r the,treatment of anemia in patients with active ...("the 103 study"). Aranesp is not,approved for use...ts were presented in an oral session at the 2007 A...
... approach for the treatment,of early and metastati...wswire-FirstCall/ - AEterna,Zentaris Inc. , a glob... endocrine therapy and oncology, today presented a...ormone-releasing,hormone (GHRH) antagonist JMR-132... Cancer Research (AACR) Annual Meeting being held,...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ten, there is a disconnect between what the doctor...sion. Sometimes this gap is so wide//, that crucia...ark because of this gap in grasping the implicatio...searchers feel the use of certain graphics by doct...
...e union cabinet Thursday approved an agreement wit...artered in Seoul for joint vaccine research.// Se...DP), IVI is an international center for research, ...stance for vaccine production in developing countr...
...e accumulation of drug resistance after the failur...ients who had previously experienced only moderate...ts failing treatment at a network of European hosp... that on average, patients who remained on a faili...
...shington - If you are obese, blame it on your gene...s shown that, //if genes called FTO portray mutati...70% chance of being over weight, as compared to pe...gene. Researchers do not have the complete story ...
Other Medicine News:Health News:Graphics- Helps Bridge Gaps in Patients’ Understanding of Medical Condition 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 3
Inquire
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)
Adhesive tape sheets for sealing multiwell plates and blocks;
Microwell Plate Accessories
Medicine Products: